Our study suggests that vaccination with native, intermediate Ki affinity peptides, which induce tumor antigen-specific CD8 T cell clonotypes of high functional avidity and killing capacity should be favored because they generate better recognition of putative tumor-derived, neo-antigen-like targets, which might become escape variants. This evidence concerns the gene CD8A and neoplasm.